Pramipexole

Pramipexole
Clinical data
Pronunciation	/ˌpræmɪˈpɛksoʊl/
Trade names	Mirapex, Mirapexin, Sifrol, others
AHFS/Drugs.com	Monograph
MedlinePlus	a697029
License data	US DailyMed: Pramipexole;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	N04BC05 (WHO) ;
Legal status
Legal status	BR: Class C1 (Other controlled substances); CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	>90%
Protein binding	15%
Elimination half-life	8–12 hours
Excretion	Urine (90%), feces (2%)
Identifiers
	IUPAC name (S)-N 6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine;
CAS Number	104632-26-0 ;
PubChem CID	119570;
IUPHAR/BPS	953;
DrugBank	DB00413 ;
ChemSpider	106770 ;
UNII	83619PEU5T;
KEGG	D05575 ; as salt: D00559 ;
ChEBI	CHEBI:8356 ;
ChEMBL	ChEMBL301265 ;
CompTox Dashboard (EPA)	DTXSID6023496 ;
ECHA InfoCard	100.124.761
Chemical and physical data
Formula	C10H17N3S
Molar mass	211.33 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n1c2c(sc1N)C[C@@H](NCCC)CC2;
	InChI InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1 ; Key:FASDKYOPVNHBLU-ZETCQYMHSA-N ;
	(verify)

Pramipexole, sold under the brand Mirapex among others, is a medication used to treat Parkinson's disease and restless legs syndrome. In Parkinson's disease it may be used alone or together with levodopa. It is taken by mouth. Pramipexole is a dopamine agonist of the non-ergoline class.

Pramipexole was approved for medical use in the United States in 1997 and was first manufactured by Pharmacia and Upjohn. It is available as a generic medication. In 2022, it was the 193rd most commonly prescribed medication in the United States, with more than 2 million prescriptions.